SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (613)4/2/1998 11:33:00 AM
From: Robohogs  Read Replies (1) | Respond to of 965
 
CNTO will have hard time staying above $40 given the news. CORR has been approved for unstable angina, an indication not even yet in phase III testing for CNTO. The market is 4x the size of the markets for which CNTO is approved. Looks like CNTO won the first battle but lost the war. Now all we need is for no partner for Avakine and no approval for Avakine. I am selling this morning.



To: FNS who wrote (613)4/3/1998 11:15:00 AM
From: PawPr  Read Replies (2) | Respond to of 965
 
I was out of town yesterday and missed all the action. My understanding is that CNTO's drug is probably the better of the two, although I'm not aware of any studies that have compared them directly. I'm actually more concerned about Merck's drug ( I think it is called Accustat ), which I believe is to go before the FDA in May.

BT


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News